Future studies will provide a systematic analysis of using a new multiplex immunofluorescence and barcode tracing approach to validate SIRPA-CD47 and CD74-MIF signaling molecules in animal models and determine their potential as therapeutic targets for MS. This evidence concerns the gene SIRPA and myeloid sarcoma.